Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2CNS 2Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Nivolumab 3fludarabine 2Ipilimumab 2tipifarnib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1pembrolizumab 1iso-sulfan blue 1fludarabine phosphate 1dostarlimab 1bempegaldesleukin 1Stem Cell Transplantation 1Sirolimus 1Mesna 1Melphalan 1Mass Spectrometry 1LY2940680 1Immunologic Techniques 1Cyclophosphamide 1Cryotherapy 1Cryosurgery 1Chromatography, High Pressure Liquid 1CTLA-4 Antigen 1Busulfan 1BI 2536 1Alemtuzumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × LY2940680 × Dermatologic × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡